Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia

J Clin Microbiol. 2007 Jun;45(6):1843-50. doi: 10.1128/JCM.00131-07. Epub 2007 Apr 25.

Abstract

Nosocomial Candida bloodstream infections rank among infections with highest mortality rates. A retrospective cohort analysis was conducted at Catholic University Hospital to estimate the risk factors for mortality of patients with candidemia. We reviewed records for patients with a Candida bloodstream infection over a 5-year period (January 2000 through December 2004). Two hundred ninety-four patients (42.1% male; mean age +/- standard deviation, 65 +/- 12 years) were studied. Patients most commonly were admitted with a surgical diagnosis (162 patients [55.1%]), had a central venous catheter (213 [72.4%]), cancer (118 [40.1%]), or diabetes (58 [19.7%]). One hundred fifty-four (52.3%) patients died within 30 days. Of 294 patients, 168 (57.1%) were infected by Candida albicans, 64 (21.7%) by Candida parapsilosis, 28 (9.5%) by Candida tropicalis, and 26 (8.8%) by Candida glabrata. When fungal isolates were tested for biofilm formation capacity, biofilm production was most commonly observed for isolates of C. tropicalis (20 of 28 patients [71.4%]), followed by C. glabrata (6 of 26 [23.1%]), C. albicans (38 of 168 [22.6%]), and C. parapsilosis (14 of 64 [21.8%]). Multivariable analysis identified inadequate antifungal therapy (odds ratio [OR], 2.35; 95% confidence interval [95% CI], 1.09 to 5.10; P = 0.03), infection with overall biofilm-forming Candida species (OR, 2.33; 95% CI, 1.26 to 4.30; P = 0.007), and Acute Physiology and Chronic Health Evaluation III scores (OR, 1.03; 95% CI, 1.01 to 1.15; P < 0.001) as independent predictors of mortality. Notably, if mortality was analyzed according to the different biofilm-forming Candida species studied, only infections caused by C. albicans (P < 0.001) and C. parapsilosis (P = 0.003) correlated with increased mortality. Together with well-established factors, Candida biofilm production was therefore shown to be associated with greater mortality of patients with candidemia, probably by preventing complete organism eradication from the blood.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Biofilms / drug effects
  • Biofilms / growth & development*
  • Candida / classification*
  • Candida / drug effects
  • Candida / growth & development*
  • Candidiasis / drug therapy
  • Candidiasis / epidemiology
  • Candidiasis / microbiology
  • Candidiasis / mortality
  • Female
  • Fungemia / drug therapy*
  • Fungemia / epidemiology
  • Fungemia / microbiology
  • Fungemia / mortality*
  • Hospitals, University
  • Humans
  • Italy / epidemiology
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Predictive Value of Tests
  • Risk Factors

Substances

  • Antifungal Agents